The goals of the gift are cancer research and human health, using a multidisciplinary approach and relying on all the Technion’s capabilities and its close ties with hospitals
The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica s microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ .
/PRNewswire/ The "Auto-Immune Diseases Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies,.
Do you have a milk allergy? Can just smelling milk trigger a dangerous reaction? Can milk allergies disappear? Dispelling common misconceptions about this common condition.